SCHEMBL5046725

SCHEMBL5046725

CCCCCCCCCCCCCCCCC(CC)(CC)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.45
GPR84 Q9NQS5 7/20 0.44
PPARG P37231 7/20 0.44
PPARD Q03181 7/20 0.44
PPARA Q07869 7/20 0.44
HDAC11 Q96DB2 5/20 0.44
TSHR P16473 4/20 0.44
PTPN1 P18031 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TLR2 O60603 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
FABP4 P15090 2/20 0.44
SLC22A6 Q4U2R8 1/20 0.44
SLC22A8 Q8TCC7 1/20 0.44
MEN1 O00255 1/20 0.44
ESR1 P03372 1/20 0.44
ALOX15 P16050 1/20 0.44
PDE4A P27815 1/20 0.44
KMT2A Q03164 1/20 0.44
PDE3A Q14432 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313593 1.00 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL5878932 1.00 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL2141772 1.00 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL5049746 1.00 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL2137337 1.00 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL20915383 1.00 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL20936490 1.00 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL20915260 1.00 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL20936507 1.00 CES2 (0.45) CES2GPR84PPARGPPARDPPARA
SCHEMBL28018719 0.98 CES2 (0.44) CES2GPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3661600-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME Epitracker, Inc. (US) 2020-06-10 EP claimed
EP-0621257-B1 Doubly branched compounds and methods of making them INST FRANCAIS DU PETROLE (FR) 1997-07-30 EP claimed
US-5434282-A Alkylation INSTITUT FRANCAIS DU PETROLE (FR) 1995-07-18 US claimed
US-20260048037-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN EPITRACKER INC (US) 2026-02-19 US disclosed
US-12440473-B2 Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain Epitracker, Inc. (US) 2025-10-14 US disclosed
US-11951088-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome Epitracker, Inc. (US) 2024-04-09 US disclosed
EP-3934639-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN Epitracker, Inc. (US) 2022-01-12 EP disclosed
US-20210386710-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN Epitracker, Inc. 2021-12-16 US disclosed
US-20210386710-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN Epitracker, Inc. 2021-12-16 US disclosed
CN-106999408-B Vanishing cream composition and application thereof 欧莱雅 2021-06-01 CN disclosed
US-10792266-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome Epitracker, Inc. (US) 2020-10-06 US disclosed
US-20020102351-A1 Process for producing magnetic disk FUJIFILM HOLDINGS CORPORATION (JP) 2002-08-01 US disclosed
EP-0621257-B1 Doubly branched compounds and methods of making them INST FRANCAIS DU PETROLE (FR) 1997-07-30 EP disclosed
US-5434282-A Alkylation INSTITUT FRANCAIS DU PETROLE (FR) 1995-07-18 US disclosed
EP-0621257-A1 Doubly branched compounds and methods of making them INSTITUT FRANCAIS DU PETROLE (FR) 1994-10-26 EP disclosed
US-4976952-A Hair conditioners, emulsifiers WELLA AKTIENGESELLSCHAFT (DE) 1990-12-11 US disclosed
US-4938950-A Water solubility WELLA AKTIENGESELLSCHAFT (DE) 1990-07-03 US disclosed
US-4931271-A HAIR CONDITIONERS, DYES, SHAMPOOS, PERMANENT WAVES; SKIN CREAMS WELLA AKTIENGESELLSCHAFT (DE) 1990-06-05 US disclosed
US-4923977-A TREATMENT OF HAIR AND SKIN WELLA AKTIENGESELLSCHAFT (DE) 1990-05-08 US disclosed
US-4845204-A Cosmetic compositions on the basis of alkyl-hydroxypropyl-substituted chitosan derivatives, new chitosan derivatives and processes for the production thereof WELLA AKTIENGESELLSCHAFT (DE) 1989-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210386710-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN SCD, FABP7, ELOVL1 CES2 205/4885GPR84 174/4885PPARG 31/4885
US-10792266-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome FABP1, FASN, GPR119 CES2 1954/4885GPR84 598/4885PPARG 82/4885
US-11951088-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome FABP1, FASN, GPR119 CES2 1954/4885GPR84 598/4885PPARG 82/4885
US-20260048037-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN CNR1, CNR2, FFAR1 CES2 133/4885GPR84 168/4885PPARG 4/4885
US-12440473-B2 Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain SCD, FABP7, ELOVL1 CES2 205/4885GPR84 174/4885PPARG 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.